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To the Editor: A 75-year-old Caucasian woman
undergoing capecitabine treatment for metastatic
breast cancer presented to the dermatology clinic
for evaluation of a pruritic eruption on the sun-
exposed areas of her body that began 2 months
after initiation of capecitabine treatment. The pa-
tient reported receiving ample sun exposure during
the summer months when she noted the onset of
the eruption. She also noted fingernail changes
over the same time frame. Her other medications
included prochlorperazine maleate 10 mg, hydro-
codone/acetaminophen 5 mg/325 mg, and denosu-
mab 120 mg subcutaneously every 4 weeks.
Examination revealed numerous violaceous, flat-
topped papules on extensor forearms, dorsal
hands, and anterior legs (Fig 1). Scaling and ery-
thema was observed in the periungual areas with
marked subungual hyperkeratosis. Diffuse ery-
thema was also noted of the palmar and plantar
surfaces. Examination of the oral cavity was unre-
markable. Fingernail clipping for histopathologic
and microbiologic evaluation of fungus was nega-
tive. Punch biopsy of the skin of her right
dorsal hand demonstrated a lichenoid interface
dermatitis with compact orthokeratosis of the
stratum corneum, multiple scattered melanophages,
and a few eosinophils in the dermis. The
clinical and histologic features were consistent
with a diagnosis of photosensitive lichenoid
drug eruption secondary to capecitabine treatment.
The patient was prescribed topical clobetasol pro-
pionate 0.05% ointment and systemic hydroxyzine,
and was recommended adherence to sun protec-
tion strategies. With these measures, she noted a
marked improvement in her eruption without any
changes in her chemotherapeutic regimen.
Capecitabine (Xeloda) is an oral prodrug of
fluorouracil (5-FU) used in the treatment of
advanced colorectal, esophageal, laryngeal, and
metastatic breast cancer.1 While 5-FU has been
used in the past for many solid tumors, it must be
administered intravenously. As an oral prodrug of
5-FU, capecitabine is easier to administer and moreOpen access under CC BY-NC-ND license.convenient for the patient; as such, its use has
increased in treating these patients.2 Some reports
have suggested a link between capecitabine use
and the development of a lichenoid photosensitive
eruption.3 Other cutaneous side effects have also
been reported, the most common of which is
palmar-plantar erythrodysesthesia, or hand-foot
syndrome, which occurs in as many as 50% of
those treated with capecitabine.4 This condition
causes tingling in the palms and soles that may
progress to burning pain 3 to 4 days later with
swelling, erythema, and possible skin ulceration.3
In addition, reports have linked the use of
capecitabine to other cutaneous presentations,
including oral lichenoid stomatitis,1 subacute
cutaneous lupus erythematosus,2 and other derma-
tologic conditions (Table I).
The reaction in our patient was unique because
of the simultaneous presentation of a photosensi-
tive lichenoid eruption, diffuse palmoplantar
erythema, and ungual toxicity, as evidenced by
the periungual erythema and subungual hyperker-
atosis. With the increasing use of capecitabine in
chemotherapeutic treatment for cancer, dermatol-
ogists should be aware of its potential cutaneous
side effects.
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Table I. Cutaneous side effects of capecitabine
Lichenoid stomatitis Lichenoid lesions associated with bullous areas on anterior
tongue and erythema on bilateral buccal cheeks.4
Nail and periungual toxicity Changes may affect the nail matrix, nail bed, and proximal nail
fold e subungual hyperkeratosis, onycholysis,
onychomadesis,1 acute paronychia, exudative discharge from
nails, and erythematous papular, and vascular lesions in nail
folds.5
Palmar-plantar erythrodysesthesia (hand-foot syndrome) Most common cutaneous reaction to capecitabine, resulting in
tingling sensation of palms and soles, followed by burning 3
to 4 days later with swelling and erythema, possibly leading
to ulceration of the skin.2
Subacute cutaneous lupus erythematosus Erythematous, nonscarring papulosquamous or annular lesions
distributed over photosensitive areas.
Other common dermatologic conditions Can induce dermatitis with pruritus, bullous eruptions, xerosis,
and alopecia. It may also cause inflammation of preexisting
actinic keratosis.3
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amicrobial pustulosis of the skin folds with
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To the Editor: Amicrobial pustulosis of the skin folds
(APF) is a rare clinical condition, often associated
with autoimmune disorders and characterized by
relapsing pustular eruptions affecting the skin folds.
Conventional treatment is based on systemic ste-
roids.1 However, relapses of the disease following
tapering or discontinuation of steroids are common.
Here we present the case of resistant APF success-
fully treated with anakinra.
A 48-year-old woman was followed for sys-
temic lupus disease since 1997; she was in
remission on low-dose prednisone and hydroxy-
chloroquine. In 2010, she presented with pustules
and exudative crust plaques in folds. Lesional
swabs were negative and skin biopsy showedspongiform pustules in the epidermis with neutro-
philic infiltrate. APF was suspected and the patient
was first treated with dapsone without resolution.
An inflammatory bowel disease developed with
neutrophilic infiltrate seen on gut histology.
Because of the gastrointestinal (GI) tract involve-
ment, anti-tumor necrosis factor (anti-TNF)-
therapy (infliximab 5 mg/kg) was initiated along
with prednisone (35 mg/day), with initial resolu-
tion of GI and skin symptoms. However, the skin
disease flared when the prednisone was tapered
to 25 mg/day, despite continuation of infliximab.
After 15 anti-TNF- infusions without improve-
ment, infliximab was switched to ustekinumab.
The patient’s skin lesions continued to flare every
time systemic steroid therapy dose was reduced,
leading to cushingoid side effects. Because of the
dependence of APF on systemic steroids and
because of its resistance to biologic therapies,
we assessed the expression level of several pro-
and anti-inflammatory-related genes in lesional
and nonlesional skin biopsies. IL-1, IL-6, IL-2
receptor (IL-2R), and IL-7R gene expression were
elevated in lesional skin, suggesting increased
cutaneous inflammation and T-cell expansion
(Table I). Therefore, the increased expression of
the cytokine IL-1, a major mediator of cutaneous
inflammation,2 prompted us to prescribe ‘‘off-
label’’ anakinra (IL-1 receptor antagonist), which
blocks either IL-1 or IL-1 activity. After 1 month
of therapy, the patient’s lesions cleared (Fig 1).
After 1 year of follow-up, the patient’s skin
condition was still in remission on anakinra
therapy.
The pathogenesis of APF and its relationship
with the underlying autoimmune disease remain
